Cargando…

Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial

BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, Olaf, Biller, H., Mueller, M., Kane, K., Rosano, M., Hanrahan, J., Hava, D. L., Hohlfeld, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533952/
https://www.ncbi.nlm.nih.gov/pubmed/26265479
http://dx.doi.org/10.1186/s40360-015-0021-1
_version_ 1782385387349475328
author Holz, Olaf
Biller, H.
Mueller, M.
Kane, K.
Rosano, M.
Hanrahan, J.
Hava, D. L.
Hohlfeld, J. M.
author_facet Holz, Olaf
Biller, H.
Mueller, M.
Kane, K.
Rosano, M.
Hanrahan, J.
Hava, D. L.
Hohlfeld, J. M.
author_sort Holz, Olaf
collection PubMed
description BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers. METHODS: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure. RESULTS: Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p ≤ 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14 + cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated. CONCLUSION: Ozone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01690949. Registered 12 September 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0021-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4533952
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45339522015-08-13 Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial Holz, Olaf Biller, H. Mueller, M. Kane, K. Rosano, M. Hanrahan, J. Hava, D. L. Hohlfeld, J. M. BMC Pharmacol Toxicol Research Article BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers. METHODS: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure. RESULTS: Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p ≤ 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14 + cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated. CONCLUSION: Ozone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01690949. Registered 12 September 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0021-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-12 /pmc/articles/PMC4533952/ /pubmed/26265479 http://dx.doi.org/10.1186/s40360-015-0021-1 Text en © Holz et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Holz, Olaf
Biller, H.
Mueller, M.
Kane, K.
Rosano, M.
Hanrahan, J.
Hava, D. L.
Hohlfeld, J. M.
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title_full Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title_fullStr Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title_full_unstemmed Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title_short Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
title_sort efficacy and safety of inhaled calcium lactate pur118 in the ozone challenge model - a clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533952/
https://www.ncbi.nlm.nih.gov/pubmed/26265479
http://dx.doi.org/10.1186/s40360-015-0021-1
work_keys_str_mv AT holzolaf efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT billerh efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT muellerm efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT kanek efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT rosanom efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT hanrahanj efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT havadl efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial
AT hohlfeldjm efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial